Seres Therapeutics to Discuss Third Quarter Financial Results
Seres Therapeutics, Inc. (NASDAQ: MCRB), a pioneering company in the realm of live biotherapeutics, is set to host an important conference call regarding its third quarter financial results. On a date soon approaching, the company's management will provide insights into its fiscal performance and highlight significant business updates.
How to Participate in the Conference Call
The scheduled conference call will take place at 8:30 a.m. ET. To partake, callers can dial in at 800-715-9871 for domestic participation or 646-307-1963 for international access. It is advisable for attendees to have the conference ID number 8471287 handy for smooth entry into the call.
Joining the Live Webcast
For those who prefer to engage through online platforms, a live audio webcast will be available, allowing listeners to access the event directly from the comfort of their own devices.
Webcast Replay Availability
Following the live event, a replay of the conference call will be made available on the Seres Therapeutics website. This recording will be accessible for a period of approximately 21 days, enabling interested parties to catch up on key discussions and insights shared during the call.
About Seres Therapeutics
Seres Therapeutics, Inc. (NASDAQ: MCRB) is at the forefront of clinical-stage innovations focused on enhancing health outcomes for medically vulnerable populations through novel live biotherapeutics. Crucially, the company was the driving force behind the development of VOWST™, marking a significant milestone as the first FDA-approved oral microbiome therapeutic, which was successfully acquired by Nestlé Health Science.
Upcoming Developments and Future Aspirations
The company is currently advancing its pipeline with SER-155. This promising therapeutic candidate has already obtained Breakthrough Therapy designation due to its potential to reduce bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The recognition of its status underscores the vital role Seres Therapeutics aims to play in improving patient survival rates and overall wellbeing.
Success in Clinical Trials
SER-155 has demonstrated remarkable efficacy in Phase 1b clinical trials, showing significant reductions in bloodstream infections and related complications compared to placebo. These findings are vital, as they showcase the therapeutic's potential to transform treatment approaches for those at heightened risk.
Expanding Target Patient Populations
Looking ahead, Seres Therapeutics has ambitious plans to broaden the applications of SER-155 and its other cultivated live biotherapeutic candidates beyond allo-HSCT. The company aims to target various other medically vulnerable groups, including patients undergoing autologous-HSCT, individuals battling cancers with neutropenia, CAR-T therapy recipients, and those facing chronic liver diseases. These plans signify a commitment to enhancing patient care in diverse settings, including intensive care units and long-term acute care facilities.
Contact Information for Investors and Media
For further inquiries, Seres Therapeutics encourages interested individuals to contact their investor relations department. Inquiries can be directed via email to IR@serestherapeutics.com. The communication will help stakeholders obtain additional information regarding the company’s operations and upcoming events.
Investor Relations
Carlo Tanzi, Ph.D., from Kendall Investor Relations is available for investor communications. He can be reached at ctanzi@kendallir.com for any further questions or insights regarding Seres Therapeutics.
Frequently Asked Questions
When will Seres Therapeutics announce its financial results?
Seres Therapeutics plans to announce its third quarter financial results soon, during a scheduled conference call.
How can I listen to the live conference call?
Participants can join the call by dialing 800-715-9871 domestically or 646-307-1963 internationally.
What is the focus of Seres Therapeutics?
Seres Therapeutics is dedicated to enhancing patient outcomes through advancing live biotherapeutics for medically vulnerable populations.
What recent approvals has Seres Therapeutics achieved?
The company achieved FDA approval for VOWST™, the first oral microbiome therapeutic, signifying a major milestone in their research.
Who can I contact for more information?
For more information, you may contact the investor relations department via email at IR@serestherapeutics.com.
